Altered levels of cytokines in patients with irritable bowel syndrome are not correlated with fatigue
Authors Vara EJ, Brokstad KA, Hausken T, Lied GA
Received 26 February 2018
Accepted for publication 20 April 2018
Published 6 July 2018 Volume 2018:11 Pages 285—291
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amy Norman
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Ellen Johanne Vara,1 Karl A Brokstad,2 Trygve Hausken,1,3,4 Gülen Arslan Lied1,3,4
1Centre of Nutrition, Department of Clinical Medicine, University of Bergen, Bergen, Norway; 2Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway; 3Section of Gastroenterology, Haukeland University Hospital, Bergen, Norway; 4National Centre of Functional Gastrointestinal Disorders, Haukeland University Hospital, Bergen, Norway
Introduction: A considerable number of patients with gastrointestinal complaints attributable to irritable bowel syndrome (IBS) have shown evidence of immune activation. Fatigue is also frequently reported by IBS patients and the condition is considered as a common comorbidity of IBS. Therefore, it is interesting to see whether these two conditions share the same pathophysiological mechanism.
Aims: To investigate the potential role of cytokine profiles in patients with IBS and the relationship between cytokine profiles and fatigue.
Materials and methods: Thirty-eight patients with IBS (32 females, 6 males, age range 18–70 years) and 22 healthy individuals (control group) (17 females, 5 males, age range 24–42 years) were included. IBS was diagnosed according to Rome III criteria, and severity of IBS symptoms and fatigue were evaluated using the Irritable Bowel Syndrome-Severity Scoring System (IBS-SSS) and Fatigue Impact Scale (FIS), respectively. FIS scores of 25 or higher were defined as fatigue. Blood samples were also taken, and the Luminex® platform (Cytokine Human Ultrasensitive Magnetic 10-Plex Panel) was used for quantifying human cytokines’ profile (granulocyte-macrophage colony-stimulating factor, interferon-γ, interleukin [IL]-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, and tumor necrosis factor [TNF]-α) in serum.
Results: The serum levels of IL-5, IL-6, IL-10, and TNF-α were significantly higher in patients with IBS compared to healthy controls (p=0.003, p=0.011, p=0.007, and p=0.02, respectively). Conversely, serum levels of cytokine IL-1β were significantly higher in the control group (p=0.03). The findings were consistent when comparing nonatopic patients with controls. Fatigue was demonstrated in 84.2% of the IBS patients. Scores of IBS-SSS were not significantly correlated with FIS scores (r=0.2, p=0.19), and they were not significantly different in patients with FIS scores >25 compared to patients with FIS scores <25 (p=0.11). None of the cytokine levels were significantly different in IBS patients with FIS scores >25 compared to IBS patients with FIS scores <25. Moreover, the cytokine levels in participants did not vary significantly between patients with diarrhea, constipation, or mixed bowel habits in multiple comparisons of patients.
Conclusions: The cytokines IL-5, IL-6, IL-10, and TNF-α may contribute to the development of IBS. However, serum levels of cytokines were not significantly different in IBS patients with fatigue compared with IBS patients without fatigue. Thus, the significance of cytokine levels may be less important than anticipated in search of common underlying mechanisms, and other factors should be explored in future studies.
Keywords: irritable bowel syndrome, fatigue, proinflammatory cytokines, immune activation
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]